Insights

Several organizations convened by Leavitt Partners met to discuss ways to support the CMS Innovation Center’s goals that further elevate the beneficiary perspective. The organizations provided their feedback on opportunities to help ensure that the Innovation Center’s objectives were met and that the agency efforts were accountable to stakeholders and transparent in their execution. These … Read more

Today, Leavitt Partners released a new policy framework that proposes a compromise path forward on implementing site-neutral payments. Medicare is an incredibly important program, providing more than 65 million Americans with access to robust health care benefits. As the program has grown, mounting concerns have been raised about its affordability for Medicare beneficiaries and the … Read more

Leavitt Partners, an HMA Company, is pleased to announce that Mark Marciante has joined the company’s digital health team of experts. He will be a director located in the company’s Washington, D.C., office. Marciante has extensive experience in digital health, successfully driving transformative initiatives for healthcare payers over the past decade. As director of engineering … Read more

The 2024 election cycle will dominate the headlines, but there will be meaningful health policy both in Congress and in the Biden Administration. This year the Leavitt Partners Political Checkpoint is a video featuring Governor Michael Leavitt and members of our D.C. team talking about short term and longer term outlook on major issues and the … Read more

The Save Rare Treatments Task Force, a new multi-sector public policy and advocacy collaboration convened by Leavitt Partners, an HMA Company, publicly launched this week and today released a letter of support for recently introduced, bipartisan, bicameral legislation. The Task Force is comprised of organizations representing persons living with rare diseases, biopharmaceutical innovators, and other … Read more

Watch Leavitt Partners Principal Elizabeth Wroe, as she explains the potential impact of a government shutdown on health care priorities. Download the presentation slides here.

In “Aggregated Precision Investment: Strengths, Weaknesses, and Potential Paths Forward,” Rebecca Nielsen, Brooke Zollinger, and Sarah Johnson from Leavitt Partners explore the feasibility of operationalizing an aggregated precision investment (API) model for social determinants of health (SDOH) interventions. The authors derive their findings from subject matter expert interviews, conversations with potential aggregators, and relevant secondary research. This article enumerates … Read more

Featured Experts

Amy Comstock Rick, former president and chief executive officer (CEO) of the Food and Drug Law Institute (FDLI), joined Leavitt Partners, an HMA Company as a principal on March 20. Rick has over 30 years of experience leading organizations, executing strategy, transforming organizational culture, building consensus, and advocating policies across constituencies. “Amy is widely respected … Read more

Data science and digital health in clinical development and operations: impact, challenges, and calls to action for the drug development ecosystem In this paper, the Medicines Development Modernization Initiative discuss how three medicines development tools (MDTs) – artificial intelligence (AI) and machine learning (ML) algorithms, digital health tools (DHTs), and augmentation of randomized controlled trial … Read more